Zepbound® and dizziness

The dizziness row, dose by dose

Zepbound®’s US label builds its main side-effect table from two 72-week, placebo-controlled trials in 2,519 adults treated with Zepbound®: SURMOUNT-1, in people without diabetes, and SURMOUNT-2, in people with type 2 diabetes. A reaction enters Table 1 only if at least 2% on Zepbound® reported it and it was more frequent than on placebo. ^[1] Dizziness passes both tests. The Canadian monograph reports the same trials with patient counts and a 1% threshold, and the European information for tirzepatide classes dizziness as common. ^[3][4]

Blood pressure: the thread that runs through it

Weight loss on Zepbound® came with lower blood pressure. In SURMOUNT-1, systolic pressure fell by 6.6, 7.7 and 7.4 mmHg on the three doses, compared with 1.0 mmHg on placebo; in SURMOUNT-2 it fell by 5.6 and 7.1 mmHg on 10 and 15 mg. ^[1] For most people that is a welcome change, but it helps explain why some feel light-headed. Section 6.1 records hypotension in 1.6% of people on Zepbound® against 0.1% on placebo, and the term covers both a general fall in pressure and a drop on standing up. ^[1]

The label then splits the finding by blood pressure treatment: 2.2% of people on Zepbound® who also took antihypertensive medicine had low blood pressure, against 1.2% of those who did not. ^[1] The Canadian monograph gives the same comparison by dose, with the highest figure, 3.4%, at 15 mg among people on blood pressure medicine. ^[3] Four in ten people in the weight trials had high blood pressure at the start, ^[1] and in the two sleep apnea trials about three quarters did (75.6% and 77.4%). ^[1] If you are in that group, light-headedness is a reason to ask your prescriber whether your blood pressure treatment still fits; it is not a reason to change it yourself.

Fluids, glucose and allergy

Three other label sections describe situations in which dizziness is a warning sign rather than a nuisance.

• Fluid loss. Most nausea, vomiting and diarrhea on Zepbound® happened while the dose was being increased. ^[1] The label warns that these can cause dehydration and acute kidney injury. ^[1] The Canadian patient information lists feeling dizzy or light-headed, extreme thirst and dark, strong-smelling urine as signs of dehydration that needs attention. ^[3] MedlinePlus counts dizziness among signs of severe dehydration. ^[10]
• Low blood sugar. In SURMOUNT-2, readings under 54 mg/dL occurred in 4.2% on Zepbound® versus 1.3% on placebo, and in 10.3% of people also on a sulfonylurea. ^[1] Dizziness or light-headedness heads the Medication Guide’s list of low blood sugar signs. ^[2]
• Allergic reaction. The Medication Guide tells you to stop Zepbound® and get help at once if dizziness or fainting arrives together with a swollen face, lips, tongue or throat, difficulty breathing or swallowing, a racing heartbeat or a severe rash. ^[2]

Findings beyond the label

A 2025 meta-analysis of 12 randomised trials of tirzepatide in type 2 diabetes found dizziness more often than with comparators (risk ratio 1.64), with a higher risk in people aged 60 or younger. ^[5] These were diabetes trials, mostly at Mounjaro® doses, so the result supports the label rather than adding Zepbound®-specific figures.

True vertigo, a spinning sensation usually tied to the inner ear, is a different question. A large US records study compared 77,259 tirzepatide users with matched non-users and found more new vestibular diagnoses, though absolute rates stayed low: 0.10% at six months and 0.19% at three years, versus 0.04% and 0.15%. ^[6] It was observational, so it cannot prove cause. An analysis of FDA spontaneous reports across six GLP-1 medicines identified dizziness as a signal and found nerve-related reports often began early, with a median of 32 days after starting; such reports show association, not causation. ^[7]

Lightheaded or spinning: other causes

MedlinePlus separates light-headedness, a feeling that you might faint, from vertigo, a sense that you or the room are moving. ^[8] Light-headedness happens when the brain briefly gets too little blood: a sudden fall in blood pressure, dehydration from vomiting, diarrhea or fever, or getting up too quickly. Flu, colds, allergies, low blood sugar and medicines that lower blood pressure can also cause it. ^[8] MedlinePlus names anti-anxiety medicines and heart and blood pressure medicines among drugs that can lower blood pressure. ^[9]

Vertigo more often comes from the inner ear, for example benign positional vertigo, an inner-ear infection after a cold, or Ménière disease. ^[8] Rarer but serious causes of dizziness include heart rhythm problems, stroke and internal bleeding, which usually bring other symptoms such as chest pain, a racing heart or changes in speech or vision. ^[8]

Steps general sources describe

The Zepbound® Medication Guide asks you to drink fluids to reduce the chance of dehydration and to call your prescriber promptly if nausea, vomiting or diarrhea persists. ^[2] People using insulin or a sulfonylurea are asked to agree a plan for spotting and handling low blood sugar with their prescriber before the first dose. ^[2]

For light-headedness on standing, MedlinePlus suggests avoiding sudden changes in posture, sitting for a few moments before getting up from lying down, and having something to hold on to. ^[8] During vertigo it advises keeping still, avoiding sudden movements and bright screens, and not driving, operating machinery or climbing until a week after symptoms have gone. ^[8] The EU product information says tirzepatide itself has no or negligible effect on driving, but asks people who also use a sulfonylurea or insulin to guard against low blood sugar at the wheel. ^[4]

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help